2016;375:2423 34. S7.4-3. Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open- label, randomised, controlled trial. Lancet. 2013;381:1107 15. S7.4-4. Sarafoff N, Martischnig A, Wealer J, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013;61:2060 6. S7.4-5. Jackson LR, Ju C, Zettler M, et al. Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary interven- tion receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE- ACS Study. J Am Coll Cardiol Intv. 2015;8:1880 9. S7.4-6. Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013;62:981 9. S7.4-7. Rubboli A, Schlitt A, Kiviniemi T, et al. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analy- sis of the AFCAS registry. Clin Cardiol. 2014;37:357 64. S7.4-8. Braun O , Bico B, Chaudhry U, et al. Concomitant use of warfa- rin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. Thromb Res. 2015;135:26 30. S7.4-9. Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015;65:1619 29. S7.4-10. Koskinas KC, R ber L, Zanchin T, et al. Duration of triple antithrom- botic therapy and outcomes among patients undergoing percutane- ous coronary intervention. J Am Coll Cardiol Intv. 2016;9:1473 83. S7.4-11. Crenshaw BS, Ward SR, Granger CB, et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. 